SG11201809317VA - Methods for classifying patients with a solid cancer - Google Patents
Methods for classifying patients with a solid cancerInfo
- Publication number
- SG11201809317VA SG11201809317VA SG11201809317VA SG11201809317VA SG11201809317VA SG 11201809317V A SG11201809317V A SG 11201809317VA SG 11201809317V A SG11201809317V A SG 11201809317VA SG 11201809317V A SG11201809317V A SG 11201809317VA SG 11201809317V A SG11201809317V A SG 11201809317VA
- Authority
- SG
- Singapore
- Prior art keywords
- paris
- international
- solid cancer
- medecine
- inserm
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6862—Ligase chain reaction [LCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111411 0 11101 HOE 010 1111 1 0 I OH 11101111110111011 11110 MAMIE Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/194556 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: (72) Inventors: GALON, Jerome; Inserm UMRS1138, Team GO1N 33/574 (2006.01) GOOF 19/00 (2011.01) 15, Cordeliers Research Center, 15 rue de Pecole de (21) International Application Number: medecine, 75006 PARIS (FR). MLECNIK, Bernhard; INSERM UMRS1138, Team 15, Cordeliers Research Cen- PCT/EP2017/061089 ter, 15 me de 1'Ecole de Medecine, 75006 Paris (FR). (22) International Filing Date: PAGES, Franck; INSERM UMRS1138,Team 15, Corde- 09 May 2017 (09.05.2017) hers Research Center, 15 Rue de 1'Ecole de Medecine, (25) Filing Language: English 75006 Paris (FR). (26) Publication Language: English (74) Agent: CABINET PLASSERAUD; 66 me de la Chaussee d'Antin, 75440 PARIS CEDEX 09 (FR). (30) Priority Data: (81) Designated States (unless otherwise indicated, for every 16305536.1 09 May 2016 (09.05.2016) EP kind of national protection available): AE, AG, AL, AM, (71) Applicants: INSERM (INSTITUT NATIONAL DE AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, LA SANTE ET DE LA RECHERCHE MEDICALE) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, [FR/FR]; 101, me de Tolbiac, 75013 PARIS (FR). DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, UNIVERSITE PIERRE ET MARIE CURIE (PARIS HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, 6) [FR/FR]; 4, Place Jussieu, 75005 PARIS (FR). KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, UNIVERSITE PARIS DESCARTES [FR/FR]; 12, me de MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, l'Ecole de Medecine, 75006 PARIS 6 (FR). UNIVERSITE PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, PARIS DIDEROT - PARIS 7 [FR/FR]; 5, me Thomas SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, Mann, 75013 PARIS (FR). ASSISTANCE PUBLIQUE TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = - HOPITAUX DE PARIS [FR/FR]; 3 Avenue Victoria, (84) Designated States (unless otherwise indicated, for every 75004 Paris (FR). kind of regional protection available): ARIPO (BW, GH, — GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = (54) Title: METHODS FOR CLASSIFYING PATIENTS WITH A SOLID CANCER (57) : The invention relates to methods for clas- present = 51 _ SELECTION sifying patients suffering from a solid cancer, particularly to meth- i f ods for the prognosis of the survival time of a patient suffering = S 2 PREPARATION from a solid cancer and/or to methods for assessing the respon- siveness of a patient suffering from a solid cancer to antitumoral — treatment. The method is based on multiple immune quantifying 53 KIT =response markers and determining to which percentile of the dis- = tribution the values correspond when compared to a reference dis- - n=n+1 — 54 tribution. Calculating the mean or median of the determined per- = ASSAY the different this to = , centiles of markers and comparing value a reference value of the mean- or median percentiles, the result of = 55 MEASURE n=n+1 4.-. , .---- which is correlated with survival or responsiveness = • I , 56 QC slt _ 57 DATA 1-1 Ss ALGORITHM SID A 511 ii . in 59 SCORE:.:MODEL DECISION 1-1 Ir -- -- 11 FIGURE 2 © ei C [Continued on next page] WO 2017/194556 Al MIDEDIMOMOIDEIROIDEMOMOHMOHIMHOMEMOIMIE UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16305536 | 2016-05-09 | ||
PCT/EP2017/061089 WO2017194556A1 (en) | 2016-05-09 | 2017-05-09 | Methods for classifying patients with a solid cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809317VA true SG11201809317VA (en) | 2018-11-29 |
Family
ID=56014938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809317VA SG11201809317VA (en) | 2016-05-09 | 2017-05-09 | Methods for classifying patients with a solid cancer |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190309369A1 (en) |
EP (1) | EP3455631B1 (en) |
JP (3) | JP7281903B2 (en) |
KR (1) | KR102245021B1 (en) |
CN (2) | CN109690314B (en) |
AU (1) | AU2017261685B2 (en) |
ES (1) | ES2808004T3 (en) |
MX (1) | MX2018013744A (en) |
PL (1) | PL3455631T3 (en) |
RU (1) | RU2745730C2 (en) |
SG (1) | SG11201809317VA (en) |
WO (1) | WO2017194556A1 (en) |
ZA (1) | ZA201807020B (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180357361A1 (en) | 2017-06-13 | 2018-12-13 | Feliks Frenkel | Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy |
EP3659110A1 (en) | 2017-07-24 | 2020-06-03 | Ventana Medical Systems, Inc. | Methods and systems for evaluation of immune cell infiltrate in tumor samples |
ES2965647T3 (en) * | 2018-01-31 | 2024-04-16 | Ventana Med Syst Inc | Procedures and systems for the evaluation of immune cell infiltrate in stage III colorectal cancer |
FR3079617B1 (en) * | 2018-03-29 | 2023-12-22 | Office National Detude Et De Rech Aerospatiales Onera | METHOD FOR DETECTING CELLS PRESENTING AT LEAST ONE ANOMALY IN A CYTOLOGICAL SAMPLE |
SG11202112712RA (en) | 2019-06-03 | 2021-12-30 | Inst Nat Sante Rech Med | Methods for modulating a treatment regimen |
CN110988324B (en) * | 2019-11-29 | 2021-08-24 | 广州市雷德医学检验实验室有限公司 | Immune state determination system, method, device and storage medium |
CN111257563B (en) * | 2020-01-22 | 2022-08-23 | 广州泛恩生物科技有限公司 | Application of CXCL13 detection agent in preparation of kit for predicting immunotherapy effect |
CN111999503B (en) * | 2020-05-28 | 2022-05-20 | 首都医科大学附属北京地坛医院 | Marker for predicting acute viral respiratory infectious disease severity and application and kit thereof |
CN113174439B (en) * | 2021-03-30 | 2022-06-28 | 中国医学科学院肿瘤医院 | Application of immune gene pair scoring system in predicting immunotherapy effect of non-small cell lung cancer patient |
US20240210404A1 (en) * | 2021-04-27 | 2024-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of lymph node metastasis and/or recurrence of patients suffering from a t1 cancer treated by endoscopic resection |
US20240254220A1 (en) * | 2021-05-13 | 2024-08-01 | CentricsBio, Inc. | Combined therapy using anti-cd300c antibody |
WO2023175366A1 (en) | 2022-03-17 | 2023-09-21 | Veracyte | Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer |
WO2023233310A1 (en) * | 2022-06-03 | 2023-12-07 | Universita' Degli Studi Di Roma "La Sapienza" | Method for determining the prognostic score in patients with metastatic renal carcinoma |
CN115747331B (en) * | 2022-09-22 | 2023-08-25 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Three-level lymphoid structure component marker combination, system and application for predicting nasopharyngeal carcinoma prognosis |
TWI826081B (en) * | 2022-10-28 | 2023-12-11 | 臺北醫學大學 | Cancer progression assessment method and system thereof |
CN117476097B (en) * | 2023-10-25 | 2024-06-07 | 中山大学附属第六医院 | Colorectal cancer prognosis and treatment response prediction model based on tertiary lymphoid structure characteristic genes, and construction method and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR053272A1 (en) * | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | DETERMINATION OF RESPONSIVES TO CHEMOTHERAPY |
EP2960342A1 (en) * | 2009-04-14 | 2015-12-30 | Nestec S.A. | Inflammatory bowel disease prognostics |
GB201021289D0 (en) | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
US9945861B2 (en) * | 2012-01-20 | 2018-04-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Methods for predicting the survival time of a patient suffering from a solid cancer based on density of B cells |
JP6449765B2 (en) * | 2012-06-14 | 2019-01-09 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Method for quantifying immune cells in tumor tissue and its application |
WO2014009535A2 (en) * | 2012-07-12 | 2014-01-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
DK2880180T3 (en) | 2012-08-06 | 2019-01-14 | Inst Nat Sante Rech Med | METHODS AND KITS TO SCREEN PATIENTS WITH CANCER |
WO2015007625A1 (en) * | 2013-07-15 | 2015-01-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for the prognosis of survival time of a patient suffering from a solid cancer |
-
2017
- 2017-05-09 JP JP2018559227A patent/JP7281903B2/en active Active
- 2017-05-09 CN CN201780028301.7A patent/CN109690314B/en active Active
- 2017-05-09 EP EP17725195.6A patent/EP3455631B1/en active Active
- 2017-05-09 CN CN202210976807.3A patent/CN115198018A/en active Pending
- 2017-05-09 AU AU2017261685A patent/AU2017261685B2/en active Active
- 2017-05-09 MX MX2018013744A patent/MX2018013744A/en unknown
- 2017-05-09 PL PL17725195T patent/PL3455631T3/en unknown
- 2017-05-09 KR KR1020187035300A patent/KR102245021B1/en active IP Right Grant
- 2017-05-09 WO PCT/EP2017/061089 patent/WO2017194556A1/en unknown
- 2017-05-09 SG SG11201809317VA patent/SG11201809317VA/en unknown
- 2017-05-09 US US16/099,451 patent/US20190309369A1/en not_active Abandoned
- 2017-05-09 RU RU2018143409A patent/RU2745730C2/en active
- 2017-05-09 ES ES17725195T patent/ES2808004T3/en active Active
-
2018
- 2018-10-22 ZA ZA2018/07020A patent/ZA201807020B/en unknown
-
2021
- 2021-11-19 JP JP2021188647A patent/JP2022027788A/en active Pending
-
2023
- 2023-12-14 JP JP2023211166A patent/JP2024019551A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20190016025A (en) | 2019-02-15 |
RU2018143409A3 (en) | 2020-06-29 |
EP3455631B1 (en) | 2020-06-24 |
CN115198018A (en) | 2022-10-18 |
EP3455631A1 (en) | 2019-03-20 |
AU2017261685B2 (en) | 2023-09-07 |
BR112018072993A2 (en) | 2019-03-06 |
PL3455631T3 (en) | 2021-04-06 |
ZA201807020B (en) | 2020-05-27 |
CN109690314B (en) | 2022-08-02 |
JP2019516979A (en) | 2019-06-20 |
US20190309369A1 (en) | 2019-10-10 |
ES2808004T3 (en) | 2021-02-25 |
KR102245021B1 (en) | 2021-04-26 |
MX2018013744A (en) | 2019-08-16 |
CN109690314A (en) | 2019-04-26 |
RU2745730C2 (en) | 2021-03-31 |
WO2017194556A1 (en) | 2017-11-16 |
JP2022027788A (en) | 2022-02-14 |
RU2018143409A (en) | 2020-06-10 |
AU2017261685A1 (en) | 2018-11-15 |
JP2024019551A (en) | 2024-02-09 |
JP7281903B2 (en) | 2023-05-26 |
BR112018072993A8 (en) | 2022-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809317VA (en) | Methods for classifying patients with a solid cancer | |
SG11201809294RA (en) | Systems and methods for sensor data analysis through machine learning | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201808820QA (en) | Methods and kits for the diagnosis and risk stratification of patients with ischemia | |
SG11201805835WA (en) | Modified oncolytic virus | |
SG11201804723WA (en) | Drowsiness onset detection | |
SG11201807195VA (en) | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity | |
SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
SG11201809606YA (en) | Combination therapy for cancer treatment | |
SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
SG11201804360XA (en) | Mat2a inhibitors for treating mtap null cancer | |
SG11201901621VA (en) | Development of spinal cord on a microfluidic chip | |
SG11201810544WA (en) | Detecting hematological disorders using cell-free dna in blood | |
SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
SG11201408107RA (en) | Method for quantifying immune cells in tumoral tissues and its applications | |
SG11201807972YA (en) | Combinations of lsd1 inhibitors for the treatment of hematological malignancies | |
SG11201810694WA (en) | Use of biomarkers in determining susceptibility to disease treatment | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201807501UA (en) | Method and system for imaging | |
SG11201408383SA (en) | Methods of detecting diseases or conditions using circulating diseased cells | |
SG11201900253TA (en) | Method and system for microbial pharmacogenomics | |
SG11201808830YA (en) | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
SG11201908472VA (en) | Compositions and methods for activating nk cells | |
SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer |